Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor agonist semaglutide ...

Nope. They’re similar, but they have different active ingredients. Ozempic is one brand name for the drug semaglutide from the pharmaceutical manufacturer Novo Nordisk. It’s FDA-approved to ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...